of 5.7 %. Grand View Research has also predicted that the global market for devices alone – that is , diagnostic , monitoring and insulin delivery products – will reach $ 35.5bn by 2024 . Grand View cited major drivers of the market as “ the growing number of diabetic patients owing to sedentary lifestyles and unhealthy food habits ”. The report also stated that the “ growing demand for advances and minimally invasive diagnostic , as well as monitoring , devices is expected to propel the market growth ”.
There ’ s certainly a demand for a new type of diagnostic product , since Grand View has found that “ in 2015 , the test-strips sub-segment captured the largest market share in the blood glucose monitoring and diagnostic devices segment ” which accounted for around 71 % of the total market as it is an area of high repeat purchases .
The diagnostic and monitoring segment , according to Grand View , was set to maintain dominance
‘ Non-invasive glucose measuring has become more of a holy grail within the market for diabetic products in recent years ’
over the next few years “ owing to the introduction of technically advanced products coupled with the high adaptation of these products in the near future ”.
Non-invasive glucose measuring has become more of a holy grail within the market for diabetic products in recent years .
Currently , most techniques to evaluate glucose levels are invasive , carrying the risk of infection . They are also considered a detached and impractical method to continually measure glucose levels .
The problems for non-invasive glucose measuring are that it remains difficult to accurately test for blood sugar without breaking the skin , as levels of sugar in the blood vary . In addition , according to the Diabetes Control and Complications Trial and Follow-up Study , intensive control
27